Tepezza Market Report 2026

Tepezza Market Overview

• The Tepezza market growth in the historic period has been driven by increasing diagnosis of thyroid eye disease, advancements in monoclonal antibody development • Market expansion is supported by increasing demand for targeted autoimmune therapies, expansion of biologic treatment pipelines • Growth Driver: Increasing Incidence Of Thyroid Diseases Driving Market Growth Due To Rising Demand For Thyroid-Associated Ophthalmopathy Treatments • Market Trend: Regulatory Advancements Expand Tepezza’s Accessibility And Impact In Thyroid Eye Disease • North America was the largest region in 2025.

What Is Covered Under Tepezza Market?

Tepezza refers to a prescription medication containing teprotumumab-trbw, a monoclonal antibody designed to target and inhibit the activity of insulin-like growth factor-1 receptor (IGF-1R). It is used for the treatment of thyroid eye disease (TED), a rare autoimmune condition that affects the muscles and tissues around the eyes, causing inflammation, swelling, and vision problems. The main types of clinical indications in tepezza are thyroid eye disease (TED), orbital inflammatory diseases, and inflammatory ocular conditions. Thyroid eye disease (TED) is an autoimmune condition in which inflammation of the tissues around the eyes occurs, often linked to thyroid disorders. It can be administered through both intravenous and subcutaneous routes and distributed through various channels such as hospital pharmacies and online pharmacies. The various end users include adults and geriatrics.

What Is The Tepezza Market Growth Forecast?

The growth in the forecast period can be attributed to increasing demand for targeted autoimmune therapies, expansion of biologic treatment pipelines, growing investments in rare disease drug development, rising focus on personalized ophthalmology treatments, increasing adoption of outpatient infusion services. Major trends in the forecast period include increasing adoption of igf-1r targeted therapies, rising use of monoclonal antibodies for autoimmune conditions, growing focus on disease-specific biologic treatments, expansion of infusion-based specialty drugs, enhanced patient monitoring during therapy.

Global Tepezza Market Segmentation

1) By Clinical Indication: Thyroid Eye Disease (TED), Orbital Inflammatory Diseases, Inflammatory Ocular Conditions 2) By Route Of Administration: Intravenous, Subcutaneous 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies 4) By End User: Adult, Geriatric

What Is The Driver Of The Tepezza Market?

Increasing incidence of thyroid diseases is expected to propel the growth of the tepezza market going forward. Thyroid diseases refer to a range of conditions that affect the structure or function of the thyroid gland, a butterfly-shaped gland located in the neck. The incidence of thyroid diseases is increasing due to several factors, including improved diagnostic techniques such as high-resolution ultrasound and fine-needle aspiration, which detect thyroid abnormalities earlier. Tepezza (teprotumumab) is used to treat thyroid eye disease by inhibiting the insulin-like growth factor-1 receptor (IGF-1R), reducing inflammation, swelling, and proptosis around the eyes. For instance, in September 2025, according to Cancer Research United Kingdom, a UK-based non-profit organization focused on cancer research and patient support, around 6,600 new cases of thyroid cancer are projected annually by 2038-2040, with incidence rates expected to rise by 27% from approximately 7.3 cases per 100,000 people per year in 2024-2026 to around 9.2 cases per 100,000. Therefore, increasing incidence of thyroid diseases is driving the growth of the tepezza industry.

Key Players In The Global Tepezza Market

Major companies operating in the tepezza market are Amgen Inc.

Global Tepezza Market Trends and Insights

Key companies in the tepezza (teprotumumab-trbw) market are obtaining regulatory approvals to expand its indications beyond Thyroid Eye Disease (TED). Regulatory approvals refer to formal authorizations from health agencies ensuring a drug's safety, efficacy, and quality for specific medical uses. For instance, in April 2023, Horizon Therapeutics plc, an Ireland-based biotechnology company, announced that the FDA has approved an update to the indication language for TEPEZZA (teprotumumab-trbw), allowing its use in patients with Thyroid Eye Disease (TED) regardless of disease activity or duration. This significant change enhances access to treatment for all eligible TED patients, as TEPEZZA is the first and only FDA-approved medication specifically for this condition. The approval is supported by data from a Phase 4 clinical trial demonstrating TEPEZZA's efficacy in reducing eye bulging in patients with long-standing TED. Horizon's CEO, Tim Walbert, highlighted that this update aims to improve timely access to therapy, ultimately benefiting patient outcomes.

What Are Latest Mergers And Acquisitions In The Tepezza Market?

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc. for $27.8 billion. With this acquisition, Amgen aims to strengthen its position as a leader in the treatment of rare and inflammatory diseases by incorporating Horizon Therapeutics' portfolio, which includes Tepezza for thyroid eye disease, Krystexxa for chronic gout, and Uplizna for autoimmune conditions, expanding its offerings in critical therapeutic areas and accelerating its growth in the inflammation space. Horizon Therapeutics plc is a US-based pharmaceutical company that offers Tepezza, which is a treatment specifically designed for thyroid eye disease (TED).

Regional Insights

North America was the largest region in the tepezza market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Tepezza Market?

The tepezza market consists of sales of pre-filled syringes, pen devices, and lyophilized powders for reconstitution. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Tepezza Market Report 2026?

The tepezza market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tepezza industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.